Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02952586 · ClinicalTrials.gov registry record · Phase 3
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 697
- Enrollment target
NCT02952586 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 697 participants.
The verdict
NCT02952586, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 697 participants
- Enrollment target
Study Summary
This is a phase 3 randomized, placebo controlled study to evaluate the safety and anti-tumor activity of Avelumab in combination with standard of care chemoradiation (SoC CRT) versus SoC CRT alone in front-line treatment of patients with locally advanced head and neck cancer.
Interventions
- DRUG Avelumab
- OTHER Chemoradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 697 participants |
| Start Date | 2016-11-28 |
| Est. Completion | 2020-08-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02952586
The ClinicalTrials.gov registry entry for NCT02952586 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 697 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avelumab is the first listed.
NCT02952586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02952586 about?
NCT02952586 is a clinical study titled "Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)". This is a phase 3 randomized, placebo controlled study to evaluate the safety and anti-tumor activity of Avelumab in combination with standard of care chemoradiation (SoC CRT) versus SoC CRT alone in front-line treatment of patients with locally advanced head and neck cancer.
What is the current status of trial NCT02952586?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 697 participants. The study started on 2016-11-28. Estimated completion is 2020-08-25.
What interventions are being tested in trial NCT02952586?
The interventions under investigation include: Avelumab (DRUG), Chemoradiation (OTHER).
Who is sponsoring clinical trial NCT02952586?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.